Stock Events

Stock Events

Tarsus Pharmaceuticals 

$59.85
18
+$2.16+3.74% Friday 20:00
+$1.05+1.75%Friday 21:11After hours

Statistics

Day High
59.95
Day Low
59.79
52W High
85.25
52W Low
38.51
Volume
35,198
Avg. Volume
-
Mkt Cap
2.57B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.94
-0.68
-0.42
-0.16
Expected EPS
-0.175544
Actual EPS
N/A

Financials

-14.72%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
451.36MRevenue
-66.42MNet Income

Analyst Ratings

94.33Average Price Target
The highest estimate is 105.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TARS. It's not an investment recommendation.
Apple
6
AAPL
Tesla
6
TSLA
Lilly(Eli) &
6
LLY
NVIDIA
5
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novartis
NVS
Mkt Cap293.94B
Novartis is a global healthcare company that competes with Tarsus Pharmaceuticals in the development of treatments for eye diseases, including therapies that could directly compete with Tarsus's pipeline products.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals is known for its innovations in ophthalmology, making it a direct competitor to Tarsus Pharmaceuticals in the eye care pharmaceutical market.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie, through its acquisition of Allergan, has a strong presence in the ophthalmology sector, competing with Tarsus Pharmaceuticals in developing treatments for eye conditions.
Bausch Health Companies
BHC
Mkt Cap1.79B
Bausch Health Companies, formerly Valeant Pharmaceuticals, has a significant portfolio of eye health products that compete with Tarsus Pharmaceuticals' offerings.
Alcon
ALC
Mkt Cap33.07B
Alcon specializes in eye care products, including pharmaceuticals and devices, making it a competitor to Tarsus Pharmaceuticals in the ophthalmology space.
Johnson & Johnson
JNJ
Mkt Cap618.61B
Johnson & Johnson, through its Vision Care division, competes with Tarsus Pharmaceuticals in the eye health market, particularly in treatments and products for eye diseases.
Rogers
ROG
Mkt Cap2.45B
Roche, with its ophthalmology division, competes in the same space as Tarsus Pharmaceuticals, particularly in the development of drugs for eye diseases.
Pfizer
PFE
Mkt Cap137.76B
Pfizer has a diversified portfolio that includes treatments for eye diseases, positioning it as a competitor to Tarsus Pharmaceuticals in the ophthalmology drug market.

About

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Show more...
CEO
Dr. Bobak R. Azamian M.D.
Employees
370
Country
United States
ISIN
US87650L1035

Listings

XNAS
US
TARS
BOATS
BOATS
TARS.BOATS

0 Comments

Share your thoughts

FAQ

What is Tarsus Pharmaceuticals stock price today?▼
The current price of TARS is $59.85 USD — it has increased by +3.74% in the past 24 hours. Watch Tarsus Pharmaceuticals stock price performance more closely on the chart.
What is Tarsus Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Tarsus Pharmaceuticals stocks are traded under the ticker TARS.
Is Tarsus Pharmaceuticals stock price growing?▼
TARS stock has risen by +2.94% compared to the previous week, the month change is a -5.24% fall, over the last year Tarsus Pharmaceuticals has showed a +38.38% increase.
What is Tarsus Pharmaceuticals market cap?▼
Today Tarsus Pharmaceuticals has the market capitalization of 2.57B
When is the next Tarsus Pharmaceuticals earnings date?▼
Tarsus Pharmaceuticals is going to release the next earnings report on August 06, 2026.
What were Tarsus Pharmaceuticals earnings last quarter?▼
TARS earnings for the last quarter are -0.16 USD per share, whereas the estimation was -0.4 USD resulting in a +60.03% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Tarsus Pharmaceuticals revenue for the last year?▼
Tarsus Pharmaceuticals revenue for the last year amounts to 451.36M USD.
What is Tarsus Pharmaceuticals net income for the last year?▼
TARS net income for the last year is -66.42M USD.
How many employees does Tarsus Pharmaceuticals have?▼
As of July 19, 2026, the company has 370 employees.
In which sector is Tarsus Pharmaceuticals located?▼
Tarsus Pharmaceuticals operates in the Health & Wellness sector.
When did Tarsus Pharmaceuticals complete a stock split?▼
Tarsus Pharmaceuticals has not had any recent stock splits.
Where is Tarsus Pharmaceuticals headquartered?▼
Tarsus Pharmaceuticals is headquartered in Irvine, United States.